Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher
12 November 2024 - 5:46AM
AllPennyStocks.com
This late-stage clinical trial company focuses on preventing
inflammation and acute organ injury. It is developing a platform of
new drugs to prevent inflammation in the kidneys, liver and
lungs...
To read the full story on AllPennyStocks.com, click
here.
Arch Biopartners (TSXV:ARCH)
Historical Stock Chart
From Feb 2025 to Mar 2025
Arch Biopartners (TSXV:ARCH)
Historical Stock Chart
From Mar 2024 to Mar 2025